Crohn's Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab.
Carlos G GonzalezToer W StevensBram VerstocktDavid J GonzalezGeert R A M D'HaensParambir S DulaiPublished in: Inflammatory bowel diseases (2024)
These results will positively impact the determination of appropriate patient treatment and inform the selection of clinical trial outcome metrics.